Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Jonathan L. Kaufman, MD, Saad Z. Usmani, MD, Jesús San-Miguel, Nizar Bahlis, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P Joy Ho, MBBS(Syd) DPhil(Oxon) FRACP FRCPA FFSc(RCPA), Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, MD, Maria Krevvata, PhD, Huiling Pei, PhD, Jon Ukropec, PhD, Thomas Renaud, Sonali Trivedi, Rachel Kobos, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1866.

https://doi.org/10.1182/blood-2019-123483

Published: 2019

Journal Articles

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Naoki Takezako, MD PhD, Naoya Kaneko, MD, Airi Hamano, Ph, Kenichi Ito, MD, Naohiro Sekiguchi, MD, Satoshi Noto, MD, Takanori Teshima, MD

Blood (2019) 134 (Supplement_1): 5595.

https://doi.org/10.1182/blood-2019-131617

Published: 2019

Journal Articles

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD PhD, Kaichi Nishiwaki, MD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, MD PhD, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof., Junichi Sakamoto,, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 4154.

https://doi.org/10.1182/blood-2019-130504

Published: 2019

Journal Articles

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Hiroyuki Takamatsu, MDPhD, Naoki Takezako, MD PhD, Rachel K Wee, Takeshi Yoroidaka, MD, Takeshi Yamashita, MD, Ryoichi Murata, MD, Kosei Matsue, MD PhD, Shinji Nakao, MD PhD

Blood (2018) 132 (Supplement 1): 258.

https://doi.org/10.1182/blood-2018-99-111250

Published: 2018

Journal Articles

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Mitsuo Hori, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD PhD, Shigeki Ito, MD PhD, Junya Kuroda, MD PhD, Mihaela Popa-McKiver, PhD, Ying-Ming Jou, Suresh G. Shelat, PhD, Masafumi Miyoshi, Kenshi Suzuki, MD PhD

Blood (2018) 132 (Supplement 1): 3260.

https://doi.org/10.1182/blood-2018-99-116225

Published: 2018

Journal Articles

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Nizar Bahlis, MD, Meletios A Dimopoulos, MD, Darrell J White, MD, Lotfi Benboubker, MD, Gordon Cook, Merav Leiba, P. Joy Ho, Kihyun Kim, MD PhD, Naoki Takezako, MD PhD, Philippe Moreau, Maria Krevvata, PhD, Christopher Chiu, PhD, Xiang Qin, Linda Okonkwo, Sonali Trivedi, Ming Qi, MD PhD, Jesus F San-Miguel, MD PhD

Blood (2018) 132 (Supplement 1): 1996.

https://doi.org/10.1182/blood-2018-99-112697

Published: 2018

Journal Articles

Phase II Trial of a Peptide Vaccine, Ocv-501 in Elderly Patients with Acute Myeloid Leukemia

Masaki Yamaguchi, MD PhD, Naoki Takezako, MD PhD, Toru Kiguchi, MD PhD, Shuichi Miyawaki, MD PhD, Yuji Heike, MD PhD, Kaori Mitsuki, Takahiro Yoshida, PhD, Ei Leen Liew, PhD MS, Tomoki Naoe, MD PhD

Blood (2018) 132 (Supplement 1): 29.

https://doi.org/10.1182/blood-2018-99-110013

Published: 2018

Journal Articles

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Meletios A. Dimopoulos, Darrell J. White, MD, Lofti Benboubker, MD, Gordon Cook, MD PhD, Merav Leiba, James Morton, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Kihyun Kim, Naoki Takezako, MD PhD, Sonali Trivedi, Kaida Wu, Tineke Casneuf, Christopher Chiu, Jordan Schecter, Philippe Moreau, MDPhD

Blood (2017) 130 (Supplement 1): 739.

https://doi.org/10.1182/blood.V130.Suppl_1.739.739

Published: 2017

Journal Articles

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Blood (2017) 130 (Supplement 1): 3121.

https://doi.org/10.1182/blood.V130.Suppl_1.3121.3121

Published: 2017

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Naoki Takezako, MD PhD, Kensuke Ohta, MD PhD, Hiroshi Handa, MD PhDChief Division, Mitsuo Hori, MD PhD, Gen Kinoshita, Suresh Shelat, Masafumi Miyoshi, Kohmei Kubo

Blood (2017) 130 (Supplement 1): 434.

https://doi.org/10.1182/blood.V130.Suppl_1.434.434

Published: 2017

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Kenshi Suzuki, MD PhD, Naoki Takezako, MD PhD, Kazutaka Sunami, MD, Yoshiaki Kuroda, MD, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Shimizu Kazuyuki, MD, Hirokazu Murakami, MD PhD

Blood (2016) 128 (22): 4436.

https://doi.org/10.1182/blood.V128.22.4436.4436

Published: 2016

Journal Articles

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Wee J Chng, MD MRCP, FRCPATH, PhD, Kihyun Kim, MD PhD, Jeffrey Huang, Chor Sang Chim, MBChB, Hiroshi Kosugi, MD PhD, Naoki Takezako, MD PhD, Junichi Sakamoto, MD PhD, Sathish Kumar Gopalakrishnan, Yuan Wei, Ling Ying Zhuo, Je-Jung Lee, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Chang-Ki Min, Jae-Hoon Lee, Brian G M Durie

Blood (2016) 128 (22): 2130.

https://doi.org/10.1182/blood.V128.22.2130.2130

Published: 2016

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Naoki Takezako, MD PhD, Michihide Tokuhira, MD PhD, Naohiro Sekiguchi, MD PhD, Yuya Kurihara, MD, Kenichi Ito, MD, Miwa Kurimoto, MD PhD, Kenshi Suzuki, MD PhD, Masahiro Kizaki, MD PhD

Blood (2016) 128 (22): 4529.

https://doi.org/10.1182/blood.V128.22.4529.4529

Published: 2016

Journal Articles

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Takashi Kumagai, MD PhD, Chiaki Nakaseko, MD, Kaichi Nishiwaki, MD PhD, Chikashi Yoshida, MD PhD, Kazuteru Ohashi, Naoki Takezako, MD PhD, Hina Takano, MD PhD, Yasuji Kouzai, MD PhD, Tadashi Murase, MD PhD, Kosei Matsue, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Wakita, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 791.

https://doi.org/10.1182/blood.V128.22.791.791

Published: 2016

Journal Articles

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

Tadao Ishida, MD, Hideo Kimura, MD PhD, Koumei Kubo, MD, Kazutaka Sunami, MD, Shuji Ozaki, MD, Naoki Takezako, MD, Hiroshi Handa, MD PhD, Hiroshi Kosugi, MD, Hirokazu Murakami, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 3043.

https://doi.org/10.1182/blood.V126.23.3043.3043

Published: 2015

Journal Articles

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Shuji Ozaki, MD PhD, Takayuki Saitoh, MD PhD, Hiroshi Handa, MD PhD, Hirokazu Murakami, MD, Kenshi Suzuki, Naoki Takezako, MD PhD, Jun Konishi, Kazutaka Sunami, Yoshiaki Kuroda, Mitsuhiro Itagaki, MD, Hideki Asaoku, MD, Eiichi Nagura, MD, Kazuyuki Shimizu, MD

Blood (2015) 126 (23): 4199.

https://doi.org/10.1182/blood.V126.23.4199.4199

Published: 2015

Journal Articles

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Rachel K Wee, Hiroyuki Takamatsu, MD PhD, Ryoichi Murata, MD, Jianbiao Zheng, PhD, Martin Moorhead, PhD, Naoki Takezako, MD PhD, Shigeki Ito, MD PhD, Toshihiro Miyamoto, MD PhD, Kenji Yokoyama, MD PhD, Kosei Matsue, MD PhD, Tsutomu Sato, MD PhD, Toshiro Kurokawa, MD PhD, Hideo Yagi, MD PhD, Yasushi Terasaki, MD PhD, Kinya Ohata, MD PhD, Takashi Yoshida, MD PhD, Malek Faham, MD PhD, Shinji Nakao, MD PhD

Blood (2015) 126 (23): 1782.

https://doi.org/10.1182/blood.V126.23.1782.1782

Published: 2015

NARROW

Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Retrospective Analysis of the Efficacy of Triplet Therapy, Including Lenalidomide, in Newly Diagnosed Multiple Myeloma Patients Who Obtained Responses Less Than VGPR after Rd Therapy

Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study

Comparison of Minimal Residual Disease Detection in Autografts of Patients with Multiple Myeloma between 8-Color Multiparameter Flow Cytometry (EuroFlow) and Next-Generation Sequencing

Elotuzumab Plus Pomalidomide/Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Japanese Subanalysis of the Randomized Phase 2 Eloquent-3 Study

Three-Year Follow up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM)

Phase II Trial of a Peptide Vaccine, Ocv-501 in Elderly Patients with Acute Myeloid Leukemia

Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux

Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma (CANDLE trial)

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

A New Prognostic Scoring System for Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients

Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial)

Interim Analysis of Phase II Study of the Bortezomib-Melphalan-Prednisolone Induction Therapy Followed By Lenalidomide-Plus-Dexamethasone Consolidation and Lenalidomide Maintenance in Non-Transplant Eligible Patients with Newly Diagnosed Symptomatic Multiple Myeloma.

A Revised International Staging System of Multiple Myeloma in the Era of Novel Agents and Autologous Stem Cell Transplantation in Japan: A Multicenter Retrospective Collaborative Study of the Japanese Society of Myeloma

A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only